简体中文
繁體中文
English
Pусский
日本語
ภาษาไทย
Tiếng Việt
Bahasa Indonesia
Español
हिन्दी
Filippiiniläinen
Français
Deutsch
Português
Türkçe
한국어
العربية
Abstract:BENGALURU, Oct 31 (Reuters) - Indias Mankind Pharma (MNKI.NS) posted an over 19% rise in second-quar
BENGALURU, Oct 31 (Reuters) - Indias Mankind Pharma (MNKI.NS) posted an over 19% rise in second-quarter profit on Tuesday, propelled by strong domestic sales and steady growth in the companys chronic drugs segment.
The countrys fourth-largest pharmaceutical company by domestic sales said its consolidated profit rose to 5.01 billion rupees ($60.2 million) for the three months ended Sept. 30 from a profit of 4.20 billion rupees a year earlier.
Analysts, on average, estimated the company to earn a profit of 5.10 billion rupees, as per LSEG data.
The companys revenue from operations rose nearly 12% to 27.08 billion rupees, led by a 7% rise in its domestic business revenue, which accounts for most of the total, to 25.29 billion rupees.
The chronic drugs segments share of domestic sales rose to 34% from 32% a year earlier, the Delhi-based company said.
Revenue from its popular consumer healthcare business segment, comprising brands such as Manforce male condoms and Prega News pregnancy test kits and which accounted for 14% of the total, also rose 2% to 1.93 billion rupees.
The companys margins on earnings before interest, taxes, depreciation and amortization (EBITDA) also improved to 25.3% from 24.5% a year earlier
The Manforce condom brand competes with Reckitt Benckiser Groups (RKT.L) Durex and TTK Groups Skore.
Shares of Mankind Pharma settled 0.6% lower on Tuesday, ahead of results. They rose 5.2% during the quarter.
($1 = 83.2434 Indian rupees)
Disclaimer:
The views in this article only represent the author's personal views, and do not constitute investment advice on this platform. This platform does not guarantee the accuracy, completeness and timeliness of the information in the article, and will not be liable for any loss caused by the use of or reliance on the information in the article.